TrialScientific reports2023
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Christoph Mamot et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this papercites it